Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 30 Aug 2022
TGA launches new look website
30 August 2022 - The new look website has gone live this evening. ...
Posted by Michael Wonder on 30 Aug 2022
TGA provisionally approves Moderna bivalent COVID-19 vaccine for use as a booster dose in adults
30 August 2022 - On 29 August 2022, the TGA provisionally approved Moderna's bivalent COVID-19 vaccine, elasomeran with imelasomeran (Spikevax Bivalent ...
Posted by Michael Wonder on 30 Aug 2022
EMA announces withdrawal of two submissions for cancer medicines
30 August 2022 - The information is somewhat buried on the EMA website. ...
Posted by Michael Wonder on 30 Aug 2022
Novartis Scemblix, with novel mechanism of action, approved by the European Commission for adult patients with chronic myeloid leukaemia
29 August 2022 - Approval based on results from pivotal Phase 3 ASCEMBL trial, in which Scemblix (asciminib) nearly doubled the ...
Posted by Michael Wonder on 30 Aug 2022
Quizartinib supplemental new drug application submitted in Japan for patients with newly diagnosed FLT3-ITD positive acute myeloid leukaemia
30 August 2022 - Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy ...
Posted by Michael Wonder on 30 Aug 2022
COVID-19 vaccines undergoing evaluation (30 August 2022)
30 August 2022 - The TGA has updated its list of the applications it has received for COVID-19 vaccines using the ...
Posted by Michael Wonder on 30 Aug 2022
FDA grants priority review to efanesoctocog alfa for people with haemophilia A
30 August 2022 - Priority review based on pivotal data from the XTEND-1 Phase 3 study. ...
Posted by Michael Wonder on 30 Aug 2022
Yukon woman paid $7,000 for private ketamine treatment, only to learn that the Yukon Government covers it
29 August 2022 - Evelyn Larson visited a private clinic in Saskatoon only to find the Yukon did cover the treatment ...
Posted by Michael Wonder on 30 Aug 2022
Swissmedic authorises Moderna's Omicron targeting bivalent booster candidate MRNA-1273.214
29 August 2022 - Switzerland becomes among the first countries in the world to approve the use of a next-generation ...
Posted by Michael Wonder on 29 Aug 2022
FDA expected to authorise Moderna, Pfizer-BioNTech Omicron boosters
29 August 2022 - The move would set the stage for the Biden administration to begin offering the reformulated vaccine shortly ...
Posted by Michael Wonder on 29 Aug 2022
FDA boldly bows to big pharma at Americans’ expense
29 August 2022 - A Wall Street Journal headline went this way: “Latest Covid Boosters Are Set to Roll Out ...
Posted by Michael Wonder on 29 Aug 2022
Amazon versus Apple: only one will rewrite the rules of health care
29 August 2022 - Big tech has had a surprisingly small impact on U.S. healthcare, so far. ...
Posted by Michael Wonder on 29 Aug 2022
European Commission approves Ranivisio (ranibizumab), a biosimilar to Lucentis
29 August 2022 - Formycon, Polpharma Biologics and Bioeq jointly announce that the European Commission has granted marketing authorisation for ...
Posted by Michael Wonder on 28 Aug 2022
Push to get 'nuclear warhead' prostate cancer drug funded
26 August 2022 - The cost of the treatment can be up to $12,000 per dose. ...
Posted by Michael Wonder on 28 Aug 2022
Ovarian cancer drug that costs up to $130k will soon be affordable for hundreds of patients
28 August 2022 - A drug that works to prolong survival for some patients with advanced ovarian cancer is being ...